Kim_2021_Yeungnam.Univ.J.Med_38_65

Reference

Title : Development of donepezil-induced hypokalemia following treatment of cognitive impairment - Kim_2021_Yeungnam.Univ.J.Med_38_65
Author(s) : Kim D , Yoon HE , Park HS , Shin SJ , Choi BS , Kim BS , Ban TH
Ref : Yeungnam Univ J Med , 38 :65 , 2021
Abstract :

Donepezil is a cholinesterase inhibitor used extensively to treat Alzheimer disease. The increased cholinergic activity is associated with adverse effects, therefore gastrointestinal symptoms, including nausea, vomiting, and diarrhea, are common. Hypokalemia is a rare adverse event that occurs in less than 1% of donepezil-treated patients. Although hypokalemia of mild and moderate grade does not present serious signs and symptoms, severe hypokalemia often results in prolonged hospitalization and mortality. Herein, we report a case of hypokalemia developed after the initiation of donepezil therapy for cognitive impairment.

PubMedSearch : Kim_2021_Yeungnam.Univ.J.Med_38_65
PubMedID: 33045804

Related information

Citations formats

Kim D, Yoon HE, Park HS, Shin SJ, Choi BS, Kim BS, Ban TH (2021)
Development of donepezil-induced hypokalemia following treatment of cognitive impairment
Yeungnam Univ J Med 38 :65

Kim D, Yoon HE, Park HS, Shin SJ, Choi BS, Kim BS, Ban TH (2021)
Yeungnam Univ J Med 38 :65